Targeting the N-terminal domain of the androgen receptor: A new approach for the treatment of advanced prostate cancer

Oncologist

Volumn 21, Issue 12, 2016, Pages 1427-1435

  Antonarakis, Emmanuel S ^a,b   Chandhasin, Chandtip ^c   Osbourne, Erica ^c   Luo, Jun ^b   Sadar, Marianne D ^d   Perabo, Frank ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ESSA Pharmaceuticals Corporation   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen receptor; EPI 506; N terminal domain; Prostate cancer

Indexed keywords

ABIRATERONE; ALISERTIB; ANDROGEN RECEPTOR; APALUTAMIDE; BIOLOGICAL MARKER; BROMODOMAIN INHIBITOR; BUPARLISIB; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; MIFEPRISTONE; NICLOSAMIDE; NIRAPARIB; OLAPARIB; ONAPRISTONE; PALBOCICLIB; RIBOCICLIB; SEVITERONEL; ANTIANDROGEN; AR PROTEIN, HUMAN; BENZHYDRYL DERIVATIVE; CHLOROHYDRIN DERIVATIVE; EPI-506; STEROID 17ALPHA MONOOXYGENASE;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CASTRATION RESISTANT PROSTATE CANCER; DNA REPAIR; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOPRECIPITATION; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; MALE; PHYSIOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN DOMAIN; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; BENZHYDRYL COMPOUNDS; CHLOROHYDRINS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN DOMAINS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE;

EID: 85006746979     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0161     Document Type: Article

References (99)

1. American Cancer Society. Cancer Facts and Figures, 2015. Available at http://www.cancer.org/Research/ CancerFactsStatistics/cancerfactsfigures2015/cancer-facts-and-figures-2015. Accessed April 1, 2016.
2. Scher HI, Morris MJ, Stadler WM et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402–1418.
3. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889–895.
4. Hu R, Lu C, Mostaghel EA et al. Distinct transcriptional programs mediated by the ligand dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72:3457–3462.
5. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942;115:1192–1200.
6. Cheng HH, Gulati R, Azad A et al. Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 2015;18:122–127.
7. Bianchini D, Lorente D, Rodriguez-Vida A et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014;50:78–84.
8. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. NEngl JMed 2014;371:1028–1038.
9. Azad AA, Eigl BJ, Murray RN et al. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015;67:23–29.
10. Thomsen FB, Røder MA, Rathenborg P et al. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 2014;48:268–275.
11. Yu Z, Chen S, Sowalsky AG et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 2014; 20:1590–1600.
12. Azad AA, Leibowitz-Amit R, Eigl BJ et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 2014;74:1544–1550.
13. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. NEngl JMed 2011;364:1995–2005.
14. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.
15. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–433.
16. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl JMed 2012;367:1187–1197.
17. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–160.
18. Maughan BL, Xhou XC, Suzman DL et al. Optimal sequencing of docetaxel and abiraterone inmenwith metastatic castration-resistant prostate cancer. Prostate 2015;75:1814–1820.
19. Nadal R, Tsai HL, Sinibaldi VJ et al. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treatedwith sequential novel androgen receptordirected therapies. Prostate 2016;76:512–520.
20. Nadal R, Zhang Z, Rahman H et al. Clinical activity of enzalutamide in Docetaxel-näıve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 2014;74:1560–1568.
21. Schweizer MT, Zhou XC, Wang H et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 66:646–652.
22. Suzman DL, Luber B, Schweizer MT et al. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 2014;74:1278–1285.
23. Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressingafter docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807–1812.
24. Noonan KL, North S, Bitting RL et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24: 1802–1807.
25. Schrader AJ, Boegemann M, Ohlmann CH et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30–36.
26. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–1177.
27. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormonesensitive prostate cancer. N Engl J Med 2015;373: 737–746.
28. Gravis G, Fizazi K, Joly F et al. Androgendeprivation therapy alone or with docetaxel in noncastrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–158.
29. Lorente D, Mateo J, Perez-Lopez R et al. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015;16:e279–e292.
30. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011;10:20.
31. Silberstein JL, Taylor MN, Antonarakis ES. Novel insights into molecular indicators of response and resistance to modern androgen-axis therapies in prostate cancer. Curr Urol Rep 2016;17:29.
32. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015; 15:701–711.
33. Bubendorf L, Kononen J, Koivisto P et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803–806.
34. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276–308.
35. Miyoshi Y, Uemura H, Fujinami K et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000;43:225–232.
36. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401–406.
37. Visakorpi T, Kallioniemi AH, Syvänen AC et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342–347.
38. Baca SC, Prandi D, Lawrence MS et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153:666–677.
39. Grasso CS, Wu YM, Robinson DR et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239–243.
40. Linja MJ, Savinainen KJ, Saramäki OR et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550–3555.
41. Qu X, Randhawa G, Friedman C et al. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet 2013;206:1–11.
42. Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11–22.
43. Cai C, Chen S, Ng P et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71:6503–6513.
44. Efstathiou E, Titus M, Tsavachidou D et al. Effects of abiraterone acetateonandrogen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30:637–643.
45. Efstathiou E, Titus M, Wen S et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 2015;67:53–60.
46. Mohler JL, Gregory CW, Ford OH 3rd et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–448.
47. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–4454.
48. Knuuttila M, Yatkin E, Kallio J et al. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am J Pathol 2014;184:2163–2173.
49. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407–6415.
50. Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 2014;5:265–273.
51. Li Y, Chan SC, Brand LJ et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483–489.
52. Mostaghel EA, Marck BT, Plymate SR et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913–5925.
53. Guo Z, Qiu Y. A new trick of an old molecule: Androgen receptor splice variants taking the stage?! Int J Biol Sci 2011;7:815–822.
54. Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69:2305–2313.
55. Sun S, Sprenger CC, Vessella RL et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715–2730.
56. Hörnberg E, Ylitalo EB, Crnalic S et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011;6:e19059.
57. Nakazawa M, Lu C, Chen Y et al. Serial bloodbased analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 2015;26:1859–1865.
58. Steinestel J, Luedeke M, Arndt A et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015 [E-pub ahead of print].
59. Antonarakis ES, Lu C, Luber B et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients withmetastatic castrationresistant prostate cancer. JAMA Oncol 2015;1: 582–591.
60. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010;12:639–657.
61. Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–1228.
62. Azad AA, Volik SV, Wyatt AW et al. Androgen receptor gene aberrations in circulating cellfree DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015;21:2315–2324.
63. Joseph JD, Lu N, Qian J et al. Aclinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020–1029.
64. Gregory CW, Johnson RT Jr., Mohler JL et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892–2898.
65. Chen G, Wang X, Zhang S et al. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005;63:395–406.
66. Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474–5478.
67. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl JMed 1995;332:1393–1398.
68. Eisermann K, Wang D, Jing Y et al. Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol 2013;2:137–147.
69. Hay CW, McEwan IJ. The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One 2012;7:e32514.
70. Chen EJ, Sowalsky AG, Gao S et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 2015;21:1273–1280.
71. Romanel A, Gasi Tandefelt D, Conteduca V et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 2015;7:312re10.
72. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28: 1481–1488.
73. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324: 787–790.
74. Bradbury RH, Acton DG, Broadbent NL et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett 2013;23: 1945–1948.
75. Clegg NJ, Wongvipat J, Joseph JD et al. ARN- 509: A novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494–1503.
76. Loddick SA, Ross SJ, Thomason AG et al. AZD3514: A small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther 2013;12:1715–1727.
77. Moilanen AM, Riikonen R, Oksala R et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 2015;5:12007.
78. Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem 2015;58:2077–2087.
79. Toren PJ, Kim S, Pham S et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther 2015;14:59–69.
80. Jenster G, van der Korput HA, van Vroonhoven C et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991;5:1396–1404.
81. Jenster G, van der Korput HA, Trapman J et al. Identification oftwo transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995;270:7341–7346.
82. Simental JA, Sar M, Lane MV et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266: 510–518.
83. McEwan IJ. Intrinsic disorder in the androgen receptor: Identification, characterisation and drugability. Mol Biosyst 2012;8:82–90.
84. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015;20:838–847.
85. Goicochea NL, Garnovskaya M, Blanton M et al. Cell-penetrating bispecific antibodies for targeting androgen receptor signaling in advanced prostate cancer. Cancer Res 2015;75(suppl 15). 642a.
86. Sadar MD, Williams DE, Mawji NR et al. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett 2008;10:4947–4950.
87. Asangani IA, Dommeti VL, Wang X et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014; 510:278–282.
88. Chan SC, Selth LA, Li Y et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res 2015;43:5880–5897.
89. Wyce A, Degenhardt Y, Bai Y et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 2013;4: 2419–2429.
90. Gao L, Schwartzman J, Gibbs A et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One 2013;8:e63563.
91. Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17:535–546.
92. DeMol E, Fenwick RB, Phang CT et al. EPI-001, a compound active against castration-resistant prostate cancer, targets transactivation Unit 5 of the androgen receptor. ACS ChemBiol 2016 [Epub ahead of print].
93. Myung JK, Banuelos CA, Fernandez JG et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 2013;123: 2948–2960.
94. Yang YC, Banuelos CA, Mawji NR et al. Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castrationresistant prostate cancer. Clin Cancer Res 2016 [E-pub ahead of print].
95. Kelvin J, Lu D, Packer D et al. Single cell analysis of AR N-terminal, AR C-terminal, and the ARv7 splice variant in the CTCs of metastatic castration resistant prostate cancer (mCRPC) patients. Cancer Res 2015;75(suppl 15):1588a.
96. Antonarakis ES, Armstrong AJ, Dehm SM et al. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis 2016;19:231–241.
97. Scher HI, Lu D, Schreiber NA et al. Association of AR-V7 on circulating tumor cells as a treatmentspecific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016 [E-pub ahead of print].
98. Markowski MC, Frick KD, Eshleman JR et al. Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. Prostate 2016 [Epubahead of print].
99. Schweizer MT, Antonarakis ES. Liquid biopsy: Clues on prostate cancer drug resistance. Sci Transl Med 2015;7:312fs45.